Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction - the SCIENCE trial.
Abbas Ali QayyumBas van KlarenboschSabina FrljakAndraz CerarGregor PoglajenDenise Traxler-WeidenauerPawel NadrowskiChristina PaitazoglouBojan VrtovecMartin W BergmannSteven A J ChamuleauWojtek WojakowskiMariann GyöngyösiAdriaan KraaijeveldKristian Schultz HansenKarsten VrangbaekErik JørgensenSteffen HelqvistFrancis Richard JoshiEllen Mønsted JohansenBjarke FollinMorten JuhlLisbeth Drozd HøjgaardAnders Bruun MathiasenAnnette EkblondMandana Haack-SørensenJens Kastrupnull nullPublished in: European journal of heart failure (2023)
The SCIENCE trial demonstrated safety of intramyocardial allogeneic CSCC_ASC therapy in patients with chronic HFrEF. However, it was not possible to improve the pre-defined endpoints and induce restoration of cardiac function or clinical symptoms.
Keyphrases
- bone marrow
- stem cell transplantation
- adipose tissue
- heart failure
- phase iii
- study protocol
- public health
- phase ii
- clinical trial
- cell therapy
- single cell
- mesenchymal stem cells
- stem cells
- insulin resistance
- high dose
- type diabetes
- left ventricular
- atrial fibrillation
- metabolic syndrome
- skeletal muscle
- acute heart failure
- depressive symptoms
- sleep quality
- placebo controlled